These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12631257)

  • 1. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
    Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
    Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
    Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
    Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
    Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
    Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
    Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
    Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
    Fahrleitner-Pammer A; Piswanger-Soelkner JC; Pieber TR; Obermayer-Pietsch BM; Pilz S; Dimai HP; Prenner G; Tscheliessnigg KH; Hauge E; Portugaller RH; Dobnig H
    J Bone Miner Res; 2009 Jul; 24(7):1335-44. PubMed ID: 19257824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].
    Tatekoshi A; Sato T; Ibata S; Hashimoto A; Kamihara Y; Horiguchi H; Ono K; Takada K; Iyama S; Takimoto R; Kobune M; Kato J
    Rinsho Ketsueki; 2014 Nov; 55(11):2271-6. PubMed ID: 25501406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma.
    Terpos E; Samarkos M; Meletis C; Apostolidou E; Tsironi M; Korovesis K; Mavrogianni D; Viniou N; Meletis J
    Int J Hematol; 2003 Nov; 78(4):344-8. PubMed ID: 14686493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
    Menssen HD; Sakalová A; Fontana A; Herrmann Z; Boewer C; Facon T; Lichinitser MR; Singer CR; Euller-Ziegler L; Wetterwald M; Fiere D; Hrubisko M; Thiel E; Delmas PD
    J Clin Oncol; 2002 May; 20(9):2353-9. PubMed ID: 11981007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
    Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
    Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
    Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.
    Halleen JM; Tiitinen SL; Ylipahkala H; Fagerlund KM; Väänänen HK
    Clin Lab; 2006; 52(9-10):499-509. PubMed ID: 17078477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
    Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
    Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
    Sauty A; Pecherstorfer M; Zimmer-Roth I; Fioroni P; Juillerat L; Markert M; Ludwig H; Leuenberger P; Burckhardt P; Thiebaud D
    Bone; 1996 Feb; 18(2):133-9. PubMed ID: 8833207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
    Rissanen JP; Suominen MI; Peng Z; Halleen JM
    Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
    Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
    Patel CG; Yee AJ; Scullen TA; Nemani N; Santo L; Richardson PG; Laubach JP; Ghobrial IM; Schlossman RL; Munshi NC; Anderson KC; Raje NS
    Clin Cancer Res; 2014 Aug; 20(15):3955-61. PubMed ID: 24958808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.